Global Markets Direct's latest Pharmaceutical and Healthcare
disease pipeline guide Escherichia
coli Infections Market Research Report, provides an overview of the
Escherichia coli Infections (Infectious Disease) pipeline landscape.
Escherichia coli (E.
coli) bacteria normally live in the intestines of healthy people and animals.
Escherichia coli infections are caused by coming into contact with the feces,
or stool, of humans or animals or drink water or eat food that has been
contaminated by feces. Symptoms include diarrhea, which may range from mild and
watery to severe and bloody, abdominal cramping, pain or tenderness, nausea and
vomiting. The predisposing factors include age, weakened immune systems and
eating certain types of food like undercooked hamburger, unpasteurized milk,
apple juice or cider and soft cheeses made from raw milk. Treatment includes
antibiotics and healthy life style.
Report Highlights
Global Markets
Direct's Pharmaceutical and Healthcare latest pipeline guide Escherichia coli Infections
- Pipeline Review, H1 2018, provides comprehensive information on the
therapeutics under development for Escherichia coli Infections (Infectious
Disease), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule type. The
guide covers the descriptive pharmacological action of the therapeutics, its
complete research and development history and latest news and press releases.
The Escherichia coli
Infections (Infectious Disease) pipeline guide also reviews of key players
involved in therapeutic development for Escherichia coli Infections and
features dormant and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules developed by
Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and
Discovery stages are 2, 1, 4, 1, 37 and 15 respectively. Similarly, the
Universities portfolio in Phase II, Preclinical and Discovery stages comprises
2, 5 and 14 molecules, respectively.
Escherichia coli
Infections (Infectious Disease) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to gain
competitive advantage. The guide is built using data and information sourced
from Global Markets Direct's proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic tracking
processes ensure that the most recent developments are captured on a real time
basis.
Scope
- The pipeline guide
provides a snapshot of the global therapeutic landscape of Escherichia coli
Infections (Infectious Disease).
- The pipeline guide
reviews pipeline therapeutics for Escherichia coli Infections (Infectious
Disease) by companies and universities/research institutes based on information
derived from company and industry-specific sources.
- The pipeline guide
covers pipeline products based on several stages of development ranging from
pre-registration till discovery and undisclosed stages.
- The pipeline guide
features descriptive drug profiles for the pipeline products which comprise,
product description, descriptive licensing and collaboration details, R&D
brief, MoA & other developmental activities.
- The pipeline guide
reviews key companies involved in Escherichia coli Infections (Infectious
Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide
evaluates Escherichia coli Infections (Infectious Disease) therapeutics based
on mechanism of action (MoA), drug target, route of administration (RoA) and
molecule type.
- The pipeline guide
encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide
reviews latest news related to pipeline therapeutics for Escherichia coli
Infections (Infectious Disease)
Reasons to buy
- Procure
strategically important competitor information, analysis, and insights to
formulate effective R&D strategies.
- Recognize emerging
players with potentially strong product portfolio and create effective
counter-strategies to gain competitive advantage.
- Find and recognize
significant and varied types of therapeutics under development for Escherichia
coli Infections (Infectious Disease).
- Classify potential
new clients or partners in the target demographic.
- Develop tactical
initiatives by understanding the focus areas of leading companies.
- Plan mergers and
acquisitions meritoriously by identifying key players and it's most promising
pipeline therapeutics.
- Formulate
corrective measures for pipeline projects by understanding Escherichia coli Infections
(Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design
in-licensing and out-licensing strategies by identifying prospective partners
with the most attractive projects to enhance and expand business potential and
scope.
- Adjust the
therapeutic portfolio by recognizing discontinued projects and understand from
the know-how what drove them from pipeline.
For more information, click on the link below:
Related Reports:-
Contact Us:-
Ken Research
Ankur Gupta, Head
Marketing & Communications
0124-4230204
